# Hematology Sector

Canonical URL: https://biopharmsignal.com/sector/hematology

Hematology includes companies focused on blood disorders, bone marrow disease, hemoglobinopathies, clotting disorders, and hematologic cancers. Businesses grouped here often sit at the intersection of rare disease, oncology, and precision medicine.

Companies currently grouped under Hematology: 8

## Recent Sector News

- 2026-07-20 10:59 EST — BMY — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-13 10:59 EST — BMY — [U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma](https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-accepts-bristol-myers-squibb-s-new-drug-applica-b21b9788) — Source: BMYBristol-Myers Squibb Company
- 2026-06-30 23:32 EST — APTO — [Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical](https://biopharmsignal.com/news/APTO/aptose-biosciences-announces-completion-of-acquisition-by-hanmi-pharmaceutical-de9f8903) — Source: Aptose Biosciences, Inc.
- 2026-06-30 12:05 EST — APVO — [Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors](https://biopharmsignal.com/news/APVO/aptevo-secures-1-5-million-non-dilutive-research-grant-from-the-andy-hill-care-f-0120aa19) — Source: Aptevo Therapeutics
- 2026-06-25 13:46 EST — BMY — [Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-report-results-for-second-quarter-2026-on-july-30-2026) — Source: BMYBristol-Myers Squibb Company
- 2026-06-25 13:46 EST — IRON — [Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-presents-positive-clinical-updates-at-the-2026-european-hematology-association-eha-annual-meeting) — Source: Disc Medicine
- 2026-06-25 13:46 EST — APTO — [Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation](https://biopharmsignal.com/news/APTO/aptose-presents-safety-response-and-mrd-clinical-data-from-tuscany-phase-1-2-clinical-trial-of-tuspetinib-triplet-therapy-in-newly-diagnosed-aml-at-the-2026-eha-congress-in-oral-presentation) — Source: Aptose Biosciences, Inc.
- 2026-06-25 13:46 EST — SNDX — [Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026](https://biopharmsignal.com/news/SNDX/syndax-showcases-revuforjr-revumenib-clinical-activity-in-multiple-acute-leukemia-subtypes-and-settings-at-eha-2026) — Source: Syndax Pharmaceuticals
- 2026-06-25 13:46 EST — SNDX — [Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology](https://biopharmsignal.com/news/SNDX/syndax-announces-publication-of-save-data-on-revuforjr-revumenib-in-combination-with-decitabine-cedazuridine-and-venetoclax-in-relapsed-refractory-npm1m-kmt2ar-and-nup98r-aml-in-the-journal-of-clinical-oncology) — Source: Syndax Pharmaceuticals
- 2026-06-25 13:46 EST — IRON — [Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria](https://biopharmsignal.com/news/IRON/disc-medicine-provides-update-from-fda-type-a-meeting-for-bitopertin-in-erythropoietic-protoporphyria) — Source: Disc Medicine
- 2026-06-25 13:46 EST — BMY — [Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease](https://biopharmsignal.com/news/BMY/mariska-hargitay-partners-with-bristol-myers-squibb-for-investigating-myeloma-awareness-campaign-to-honor-her-father-20-years-after-losing-him-to-the-disease) — Source: BMYBristol-Myers Squibb Company
- 2026-06-25 13:46 EST — SNDX — [Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes](https://biopharmsignal.com/news/SNDX/syndax-announces-private-placement-of-250-0-million-of-convertible-senior-notes) — Source: Syndax Pharmaceuticals
- 2026-06-25 13:46 EST — IRON — [Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients](https://biopharmsignal.com/news/IRON/disc-medicine-launches-expanded-access-program-for-bitopertin-for-epp-patients) — Source: Disc Medicine
- 2026-06-25 13:46 EST — IRON — [Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-presents-updated-positive-data-from-rally-mf-phase-2-trial-in-patients-with-myelofibrosis-mf-and-anemia-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting) — Source: Disc Medicine
- 2026-06-25 13:46 EST — SNDX — [Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data](https://biopharmsignal.com/news/SNDX/syndax-highlights-revuforjr-revumenib-data-presented-at-asco-2026-including-an-oral-presentation-of-post-transplant-data) — Source: Syndax Pharmaceuticals
- 2026-06-25 13:46 EST — BMY — [Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma](https://biopharmsignal.com/news/BMY/izalontamab-brengitecan-iza-bren-demonstrates-statistically-significant-and-clinically-meaningful-improvements-in-overall-survival-and-progression-free-survival-in-patients-with-triple-negative-breast-cancer-and-esophageal-squamous-cell-carcinoma) — Source: BMYBristol-Myers Squibb Company
- 2026-06-25 13:46 EST — SNDX — [Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026](https://biopharmsignal.com/news/SNDX/syndax-to-host-randd-day-highlighting-its-late-stage-programs-and-early-stage-assets-on-july-14-2026) — Source: Syndax Pharmaceuticals
- 2026-06-25 13:46 EST — BMY — [Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-announces-opdivor-nivolumab-in-combination-with-avd-receives-expanded-eu-label-with-approval-in-frontline-advanced-classical-hodgkin-lymphoma) — Source: BMYBristol-Myers Squibb Company
- 2026-06-25 13:46 EST — BMY — [U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)](https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-accepts-for-priority-review-bristol-myers-squibb-s-supplemental-new-drug-application-for-camzyos-mavacamten-to-treat-adolescents-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-ohcm) — Source: BMYBristol-Myers Squibb Company
- 2026-06-25 13:46 EST — BMY — [Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial](https://biopharmsignal.com/news/BMY/global-data-for-biontech-and-bristol-myers-squibb-s-pd-l1xvegf-a-bispecific-pumitamig-shows-encouraging-efficacy-in-patients-with-non-small-cell-lung-cancer-in-rosetta-lung-02-trial) — Source: BMYBristol-Myers Squibb Company

## Companies

- [APVO](https://biopharmsignal.com/company/APVO) — Aptevo Therapeutics
- [APTO](https://biopharmsignal.com/company/APTO) — Aptose Biosciences, Inc.
- [BMY](https://biopharmsignal.com/company/BMY) — BMYBristol-Myers Squibb Company
- [IRON](https://biopharmsignal.com/company/IRON) — Disc Medicine
- [KROS](https://biopharmsignal.com/company/KROS) — Keros Therapeutics
- [MRKR](https://biopharmsignal.com/company/MRKR) — Marker Therapeutics
- [NVO](https://biopharmsignal.com/company/NVO) — Novo Nordisk
- [SNDX](https://biopharmsignal.com/company/SNDX) — Syndax Pharmaceuticals